Evidence map›Paper›PMID 34514342›Full record

ArticleJournal of Alzheimer's disease reports2021

Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer's Disease in the FIT-AD Trial.

Danni Li, Lin Zhang, Nathaniel W Nelson, Michelle M Mielke, Fang Yu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. AD-related plasma biomarkers in centenarians: links to cognition and neuropathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Danni LiDepartment of Lab Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Lin ZhangSchool of Public Health, Division of Biostatistics, University of Minnesota, Minneapolis, MN, USA.
Nathaniel W NelsonGraduate School of Professional Psychology, University of St. Thomas, Minnesota, St. Paul, MN, USA.
Michelle M MielkeDepartments of Health Sciences Research and Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Fang YuEdson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA.
University of Minnesota · USArizona State University · USMayo Clinic · USUniversity of St. Thomas - Minnesota · US

Funding

Aerobic Exercise in Alzheimer's Disease: Cognition and Hippocampal Volume EffectsR01AG043392 · NIA · UNIVERSITY OF MINNESOTA · PI YU, FANG · 2013 to 2018
$3.2M
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive ImpairmentR01AG059654 · NIA · UNIVERSITY OF MINNESOTA · PI LI, DANNI · 2018 to 2022
$2.2M
NIA NIH HHS R01 AG043392NIA NIH HHS R01 AG059654
6 · The paper itself

Abstract

backgroundUtilities of blood-based biomarkers in Alzheimer's disease (AD) clinical trials remain unknown.

objectiveTo evaluate the ability of plasma neurofilament light chain (NfL) to predict future declines in cognition and activities of daily living (ADL) outcomes in 26 older adults with mild-to-moderate AD dementia from the FIT-AD Trial.

methodsPlasma NfL was measured at baseline and 3 and 6 months. Cognition and ADL were assessed using the AD Assessment Scale-Cognition (ADAS-Cog) and AD Uniform Dataset Instruments and Disability Assessment for Dementia (DAD), respectively, at baseline, 3, 6, 9, and 12 months. Linear mixed effects models were used to examine the associations between baseline or change in plasma NfL and changes in outcomes.

resultsHigher baseline plasma NfL was associated with greater rate of decline in ADAS-Cog from baseline to 6 months (standardized estimate of 0.00462,

conclusionThis study demonstrated that plasma NfL might have the potential to predict cognitive and function decline up to 12 months. However, future studies with bigger sample sizes need to confirm the findings.

Indexed as

Activities of daily livingADAS-CogAlzheimer’s diseaseblood-based biomarkerscognitionlongitudinalneurofilament light

Identifiers

PMID34514342
PMCPMC8385429
OpenAlexW3168061270

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.